SCHEMBL8202307

SCHEMBL8202307

C[C@H]1CC2(CCN1)C(N1CCC1)=NC(=O)N2c1cccc(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.37
BACE1 P56817 5/20 0.35
MAPK1 P28482 1/20 0.34
BACE2 Q9Y5Z0 1/20 0.33
CYP3A4 P08684 3/20 0.32
CYP1A2 P05177 2/20 0.32
CYP2C9 P11712 2/20 0.32
TSHR P16473 2/20 0.32
CYP2C19 P33261 2/20 0.32
USP2 O75604 1/20 0.32
OPRL1 P41146 1/20 0.32
ADAMTS5 Q9UNA0 2/20 0.31
ALDH1A1 P00352 2/20 0.31
POLB P06746 2/20 0.31
MAPT P10636 2/20 0.31
GAA P10253 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3492017 1.00 ALOX5 (0.37) ALOX5BACE1MAPK1BACE2CYP3A4
SCHEMBL3492021 1.00 ALOX5 (0.37) ALOX5BACE1MAPK1BACE2CYP3A4
SCHEMBL8240030 0.83 ALOX5 (0.40) ALOX5BACE1MAPK1OPRL1ALDH1A1
SCHEMBL760177 0.82 ALOX5 (0.38) ALOX5BACE1MAPK1BACE2OPRL1
SCHEMBL3891190 0.81 CYP3A4 (0.36) BACE1MAPK1BACE2CYP3A4CYP1A2
SCHEMBL3891195 0.81 CYP3A4 (0.36) BACE1MAPK1BACE2CYP3A4CYP1A2
SCHEMBL3496401 0.81 BACE1 (0.40) BACE1
SCHEMBL13461566 0.80 BACE1 (0.38) BACE1MAPK1
SCHEMBL3494499 0.79 PIK3C3 (0.41) BACE1USP2ALDH1A1GAAKMT2A
SCHEMBL760114 0.79 ADORA3 (0.41) ALOX5BACE1MAPK1BACE2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293759-B2 Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme, Corp. (US) 2012-10-23 US disclosed
US-8293759-B2 Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme, Corp. (US) 2012-10-23 US disclosed
EP-2091328-B1 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2011-12-28 EP disclosed
US-20100069419-A1 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LLC 2010-03-18 US disclosed
US-20100069419-A1 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LLC 2010-03-18 US disclosed
WO-2008054698-A2 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069419-A1 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BACE1, BACE2, APP ALOX5 1842/4885BACE1 1/4885MAPK1 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.